SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 26, 2004
Progenics Pharmaceuticals, Inc.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-23143 13-3379479
---------------------------- ------------------------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Road, Tarrytown, New York 10591
------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (914) 789-2800
(Former name or former address, if changed since last report.)
Item 7. Financial Statements and Exhibits
(c) Exhibits
Exhibit 99.1 Description
Press Release dated May 26, 2004 (filed herewith).
Item 9. Regulation FD Disclosure.
On May 26, 2004, Progenics Pharmaceuticals, Inc. issued a press release
announcing the reelection of all eight current member of the Board of Directors
to serve for an additional one-year term and at the Annual Meeting of
Shareholders, Pricewaterhouse Coopers LLP was ratified to continue to serve as
the Company's independent auditor for another year. In addition, the Company
announced the departure of Philip K. Yachmetz, Vice President and General
Counsel. A copy of the press release is attached as Exhibit 99.1.
The information furnished pursuant to Item 9 in this Form 8-K shall not
be deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934 or otherwise subject to the liabilities of that Section,
unless we specifically incorporate it by reference in a document filed under the
Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no
duty or obligation to publicly update or revise the information furnished
pursuant to Item 9 in this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ ROBERT A. MCKINNEY
-------------------------------
Robert A. McKinney
Vice President, Finance &
Operations and Treasurer
Date: May 26, 2004